Personalis (PSNL) reported preliminary Q4 revenue Thursday of $17 million to $18 million.
Analysts surveyed by FactSet expected $17.6 million.
For 2025, it reported preliminary revenue of $69 million to $70 million, down from $84.6 million a year earlier.
Analysts surveyed by FactSet expect $70 million.
The biotech firm ended 2025 with around $240 million in cash, cash equivalents, and short-term investments.
Shares of the company were down 2.7 in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments